In this interview Dr. Miguel Blanquer Blanquer (Hematologist at Hospital Clínico Universitario Virgen de la Arrixaca – Murcian Health Service) shares his clinical perspective on congenital anemias, the limitations of current treatments, and the hope represented by innovative approaches such as NANEMIAR.

Murcian Health Service participates as Affiliated Entity of FFIS-IMIB partner in the NANEMIAR project.

FIRST, WHAT IS THE BIGGEST CHALLENGE IN TREATING CONGENITAL ANEMIAS TODAY?​

“Congenital anemias, such as β-thalassemia, are rare inherited disorders that severely impair red blood cell production. For many patients, the only curative option is bone marrow transplantation, which is feasible for very few due to donor compatibility and the associated risks. Most treatments rely on lifelong transfusions and iron chelation, which come with significant complications and impact quality of life.”

HOW DOES THIS AFFECT YOUR DAILY CLINICAL PRACTICE?

“We see young patients who require frequent hospital visits for transfusions. This not only limits their independence but also exposes them to risks like iron overload and infections. Despite advances, curative options remain extremely limited, and the psychological burden on families is enormous.”

WHY DID YOU CHOOSE HEMATOLOGY AND CELL THERAPY?​

“I have always been passionate about improving outcomes for patients with severe blood disorders. Hematology offers a unique opportunity to combine clinical care with cutting-edge research. Working in transplantation and progenitor cell therapy has shown me how innovation can truly change lives.”

 WHAT DOES NANEMIAR MEAN TO YOU?​  

“NANEMIAR represents hope. It is an innovative approach using mRNA-based nanomedicine to restore normal erythropoiesis. For clinicians, this could mean moving beyond transfusion dependency towards a safer, more effective therapy. Being part of this European consortium allows us to bring the latest science directly to our patients.”    

Source information:​
NANEMIAR project